Compile Data Set for Download or QSAR
Report error Found 757 Enz. Inhib. hit(s) with all data for entry = 10792
TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569236(US11427563, Compound 103)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569281(US11427563, Compound 96 | US11427563, Compound 32 ...)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569281(US11427563, Compound 96 | US11427563, Compound 32 ...)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569235(US11427563, Compound 10 | US11427563, Compound 143...)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569235(US11427563, Compound 10 | US11427563, Compound 143...)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569296(US11427563, Compound 51)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569312(US11427563, Compound 68)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569313(US11427563, Compound 69)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569288(US11427563, Compound 93 | US11427563, Compound 20)
Affinity DataIC50: 0nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569236(US11427563, Compound 103)
Affinity DataIC50: 0nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569239(US11427563, Compound 116 | US11427563, Compound 10...)
Affinity DataIC50: 0nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569243(US11427563, Compound 52 | US11427563, Compound 110)
Affinity DataIC50: 0nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569325(US11427563, Compound 121 | US11427563, Compound 81)
Affinity DataIC50: 0nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569288(US11427563, Compound 93 | US11427563, Compound 20)
Affinity DataIC50: 0nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569315(US11427563, Compound 70)
Affinity DataIC50: 0.100nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569239(US11427563, Compound 116 | US11427563, Compound 10...)
Affinity DataIC50: 0.200nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569295(US11427563, Compound 49)
Affinity DataIC50: 0.200nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569298(US11427563, Compound 62 | US11427563, Compound 53)
Affinity DataIC50: 0.200nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.25nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.25nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.25nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569281(US11427563, Compound 96 | US11427563, Compound 32 ...)
Affinity DataIC50: 0.350nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569281(US11427563, Compound 96 | US11427563, Compound 32 ...)
Affinity DataIC50: 0.350nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569281(US11427563, Compound 96 | US11427563, Compound 32 ...)
Affinity DataIC50: 0.350nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569282(US11427563, Compound 84 | US11427563, Compound 174)
Affinity DataIC50: 0.400nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569282(US11427563, Compound 84 | US11427563, Compound 174)
Affinity DataIC50: 0.400nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 0.400nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569281(US11427563, Compound 96 | US11427563, Compound 32 ...)
Affinity DataIC50: 0.400nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569298(US11427563, Compound 62 | US11427563, Compound 53)
Affinity DataIC50: 0.400nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569251(US11427563, Compound 120 | US11427563, Compound 11...)
Affinity DataIC50: 0.400nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569271(US11427563, Compound 86 | US11427563, Compound 146)
Affinity DataIC50: 0.400nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569271(US11427563, Compound 86 | US11427563, Compound 146)
Affinity DataIC50: 0.400nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569244(US11427563, Compound 16b | US11427563, Compound 16...)
Affinity DataIC50: 0.440nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569233(US11427563, Compound 114 | US11427563, Compound 13...)
Affinity DataIC50: 0.440nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569350(US11427563, Compound 125)
Affinity DataIC50: 0.5nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569284(US11427563, Compound 83 | US11427563, Compound 176)
Affinity DataIC50: 0.5nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetRho-associated protein kinase 2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569284(US11427563, Compound 83 | US11427563, Compound 176)
Affinity DataIC50: 0.5nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569251(US11427563, Compound 120 | US11427563, Compound 11...)
Affinity DataIC50: 0.600nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569268(US11427563, Compound 85 | US11427563, Compound 7 |...)
Affinity DataIC50: 0.600nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569304(US11427563, Compound 78 | US11427563, Compound 59)
Affinity DataIC50: 0.600nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetInhibitor of nuclear factor kappa-B kinase subunit beta(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569268(US11427563, Compound 85 | US11427563, Compound 7 |...)
Affinity DataIC50: 0.600nMAssay Description:All compounds were initially prepared as 10 mM stocks in anhydrous dimethylsulfoxide (DMSO). A 20 μl aliquot of the 10 mM solutions was transfer...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569251(US11427563, Compound 120 | US11427563, Compound 11...)
Affinity DataIC50: 0.600nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569334(US11427563, Compound 8)
Affinity DataIC50: 0.650nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569338(US11427563, Compound 94)
Affinity DataIC50: 0.650nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569239(US11427563, Compound 116 | US11427563, Compound 10...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569239(US11427563, Compound 116 | US11427563, Compound 10...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Aerie Pharmaceuticals

US Patent
LigandPNGBDBM569240(US11427563, Compound 112 | US11427563, Compound 14...)
Affinity DataIC50: 0.700nMAssay Description:Compounds were prepared in the exact same manner as described in the ROCK Kinase Assay with the exception to the substrate and enzyme. The JAK 2× sub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 757 total ) | Next | Last >>
Jump to: